Clinical trials recruiting for Systemic lupus erythematosus
119
Recruiting trials
38
US states with sites
52
Countries
16%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Anifrolumab | 7 |
| Cyclophosphamide | 3 |
| Belimumab | 2 |
| CD19 CAR-T cells | 2 |
| CD19 Universal CAR-γδ T Cells | 2 |
| Fludarabine | 2 |
| A-319 | 1 |
| AB-101 | 1 |
| ABBV-319 | 1 |
| ABBV-519 | 1 |
| AZD5492 | 1 |
| Alnuctamab | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 18 |
| California | 14 |
| New York | 13 |
| Florida | 12 |
| North Carolina | 12 |
| Illinois | 10 |
| Maryland | 8 |
| Pennsylvania | 8 |
| Alabama | 7 |
| Ohio | 7 |
| Arizona | 6 |
| Georgia | 6 |
Top cities
New York, New York 11Houston, Texas 10Clearwater, Florida 7Tampa, Florida 7Oklahoma City, Oklahoma 6Anniston, Alabama 5Chicago, Illinois 5Memphis, Tennessee 5Miami, Florida 5Philadelphia, Pennsylvania 5
Self-screener
Recruiting trials
- " TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
- A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
- A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
- A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
- A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
- A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
- A Study of E6742 in Participants With Systemic Lupus Erythematosus
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
- A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
- A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
- A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
- A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
- A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
- A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Alnuctamab for Refractory SLE (LATTE Study)
- An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
- An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- Anifrolumab Malignancy and Serious Infections Study
- Anifrolumab Pregnancy Study
- Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
- Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments
- Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
- BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Biomarker Development for Autoimmune Disorders Involving the Kidneys
- Biomarkers in Inflammatory Rheumatic Diseases Diagnosis
- CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
- CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
- CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus
- Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
- Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
- Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
- CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
- Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders
- Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
- Duke Lupus Registry
- EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
- Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
- Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus
- Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
- Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
- Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
- Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
- Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
- Fatigue in Lupus Intervention Programmes (FLIP)
- Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus
- Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU
- Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
- HEALTH Home Urinalysis Testing
- HLA Antibodies in Systemic Lupus Erythematosus
- ILD-SARDs Registry and Biorepository
- Immun4Cure Cohort of Autoimmune Diseases
- Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy
- Intervention to Improve Communication and Medication Adherence in Lupus
- LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
- Long-Term Outcomes in SLE at Peking University People's Hospital
- MTS109 in Patients With Refractory Autoimmune Diseases
- Maternal Autoimmune Disease Research Alliance (MADRA) Registry
- Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
- Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
- Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
- Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
- Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
- REACT-01: Reversing Autoimmunity Through Cell Therapy
- RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS
- Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
- Reduced Vaccine Response to HZ/su in SLE
- Rheumatology Patient Registry and Biorepository
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
- Safety and Efficacy of ONT01 in Lupus
- Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)
- Safety of Administering Isoniazid to SLE Patients to Prevent TB
- Safety of the Herpes Zoster Subunit Vaccine in Lupus
- Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
- Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
- Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
- Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
- Study of CD19 CAR-T Therapy for Refractory SLE
- Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus
- Study of Systemic Lupus Erythematosus
Related conditions
Trials recruiting for Systemic lupus erythematosus often also study these conditions. Each links to its own recruiting-trial list.
Lupus 332Rheumatoid arthritis 314Systemic Sclerosis 27Lupus Nephritis 49Sjogren's Syndrome 25Antiphospholipid Syndrome 10Psoriatic arthritis 45Psoriasis 233Systemic Sclerosis (SSc) 28Dermatomyositis 10
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Systemic lupus erythematosus trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.